Compare Stocks: COGT, UTHR, GMAB, and ASND

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ASND Ascendis Pharma A/S	$266.52 -0.3%	$257.46	$186.05 ▼ $282.15	$16.69B	0.35	669,635 shs	75,727 shs
COGT Cogent Biosciences	$34.28 -0.9%	$38.63	$11.60 ▼ $43.73	$5.95B	0.31	2.17 million shs	65,313 shs
GMAB Genmab A/S	$34.22 0.0%	$30.15	$23.62 ▼ $35.43	$21.36B	0.84	1.95 million shs	106,831 shs
UTHR United Therapeutics	$480.39 -2.4%	$528.12	$375.61 ▼ $609.35	$20.66B	0.56	491,876 shs	88,828 shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ASND Ascendis Pharma A/S	+2.71%	+6.82%	+9.80%	+22.15%	+34.22%
COGT Cogent Biosciences	-0.32%	-5.86%	-11.04%	+5.43%	+188.08%
GMAB Genmab A/S	+2.79%	+1.39%	+19.32%	+38.37%	+32.17%
UTHR United Therapeutics	-4.03%	-4.77%	-4.70%	-10.16%	+21.54%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ASND Ascendis Pharma A/S	$266.52 -0.3%	$257.46	$186.05 ▼ $282.15	$16.69B	0.35	669,635 shs	75,727 shs
COGT Cogent Biosciences	$34.28 -0.9%	$38.63	$11.60 ▼ $43.73	$5.95B	0.31	2.17 million shs	65,313 shs
GMAB Genmab A/S	$34.22 0.0%	$30.15	$23.62 ▼ $35.43	$21.36B	0.84	1.95 million shs	106,831 shs
UTHR United Therapeutics	$480.39 -2.4%	$528.12	$375.61 ▼ $609.35	$20.66B	0.56	491,876 shs	88,828 shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ASND Ascendis Pharma A/S	+2.71%	+6.82%	+9.80%	+22.15%	+34.22%
COGT Cogent Biosciences	-0.32%	-5.86%	-11.04%	+5.43%	+188.08%
GMAB Genmab A/S	+2.79%	+1.39%	+19.32%	+38.37%	+32.17%
UTHR United Therapeutics	-4.03%	-4.77%	-4.70%	-10.16%	+21.54%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ASND Ascendis Pharma A/S	3.05	Buy	$310.05	16.33% Upside
COGT Cogent Biosciences	2.75	Moderate Buy	$51.56	50.42% Upside
GMAB Genmab A/S	2.85	Moderate Buy	$39.50	15.45% Upside
UTHR United Therapeutics	2.85	Moderate Buy	$646.00	34.47% Upside

Current Analyst Ratings Breakdown

Latest COGT, UTHR, GMAB, and ASND Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/1/2026	ASND Ascendis Pharma A/S	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$304.00 ➝ $312.00
9/1/2026	GMAB Genmab A/S	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C) ➝ Hold (C+)
9/1/2026	ASND Ascendis Pharma A/S	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$275.00 ➝ $273.00
9/1/2026	ASND Ascendis Pharma A/S	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$327.00
8/31/2026	ASND Ascendis Pharma A/S	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$333.00 ➝ $330.00
8/31/2026	ASND Ascendis Pharma A/S	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$328.00 ➝ $326.00
8/31/2026	ASND Ascendis Pharma A/S	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$345.00
8/31/2026	ASND Ascendis Pharma A/S	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$306.00 ➝ $304.00
8/27/2026	UTHR United Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy (B) ➝ Buy (B-)
8/27/2026	ASND Ascendis Pharma A/S	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$345.00
8/27/2026	ASND Ascendis Pharma A/S	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$345.00

(Data available from 9/3/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ASND Ascendis Pharma A/S	$814.57M	20.41	N/A	N/A	$26.78 per share	9.95
COGT Cogent Biosciences	N/A	N/A	N/A	N/A	$2.69 per share	N/A
GMAB Genmab A/S	$3.72B	5.74	$1.65 per share	20.68	$9.55 per share	3.58
UTHR United Therapeutics	$3.18B	6.47	$30.91 per share	15.54	$149.22 per share	3.22

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ASND Ascendis Pharma A/S	-$258M	$12.89	20.75	29.22	N/A	70.99%	32.54%	7.71%	11/11/2026 (Estimated)
COGT Cogent Biosciences	-$328.94M	-$2.16	N/A	N/A	N/A	N/A	-84.47%	-47.72%	11/6/2026 (Estimated)
GMAB Genmab A/S	$963M	$1.27	26.97	21.12	1.98	19.08%	14.89%	7.73%	11/5/2026 (Estimated)
UTHR United Therapeutics	$1.33B	$27.95	17.23	16.19	2.56	41.56%	20.18%	17.98%	11/4/2026 (Estimated)

Latest COGT, UTHR, GMAB, and ASND Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2026	Q2 2026	ASND Ascendis Pharma A/S	$1.71	$1.0270	-$0.6830	$3.23	$376.75 million	$387.22 million
8/10/2026	Q2 2026	COGT Cogent Biosciences	-$0.5550	-$0.52	+$0.0350	-$0.52	$0.00 million	N/A
8/6/2026	Q2 2026	GMAB Genmab A/S	$0.37	$0.54	+$0.17	$0.4910	$1.12 billion	$1.16 billion
8/5/2026	Q2 2026	UTHR United Therapeutics	$6.86	$7.27	+$0.41	$7.27	$804.65 million	$783.30 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ASND Ascendis Pharma A/S	N/A	N/A	N/A	N/A	N/A
COGT Cogent Biosciences	N/A	N/A	N/A	N/A	N/A
GMAB Genmab A/S	N/A	N/A	N/A	N/A	N/A
UTHR United Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ASND Ascendis Pharma A/S	0.27	2.99	2.32
COGT Cogent Biosciences	0.48	13.57	13.57
GMAB Genmab A/S	0.81	2.46	2.44
UTHR United Therapeutics	N/A	5.73	5.41

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ASND Ascendis Pharma A/S	N/A
COGT Cogent Biosciences	N/A
GMAB Genmab A/S	7.07%
UTHR United Therapeutics	94.08%

Insider Ownership

Company	Insider Ownership
ASND Ascendis Pharma A/S	40.00%
COGT Cogent Biosciences	6.59%
GMAB Genmab A/S	1.54%
UTHR United Therapeutics	8.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ASND Ascendis Pharma A/S	1,189	62.38 million	37.43 million	Optionable
COGT Cogent Biosciences	80	173.52 million	162.09 million	Optionable
GMAB Genmab A/S	3,029	623.78 million	614.17 million	Optionable
UTHR United Therapeutics	1,400	42.89 million	39.20 million	Optionable

COGT, UTHR, GMAB, and ASND Headlines

Recent News About These Companies

United Therapeutics Corporation Announces FDA Acceptance of Supplemental New Drug Application for Nebulized Tyvaso® to Treat Idiopathic Pulmonary Fibrosis

September 2 at 3:21 PM | rutlandherald.comR

United Therapeutics Announces FDA Acceptance Of SNDA For Nebulized Tyvaso In IPF

September 2 at 3:21 PM | rttnews.com

United Therapeutics bid to expand nebulized Tyvaso label gets FDA review

September 2 at 3:21 PM | msn.com

United Therapeutics Slides as Investors Weigh Insider Selling Against a New Regulatory Milestone

September 2 at 12:31 PM | quiverquant.comQ

United Therapeutics (NASDAQ:UTHR) Shares Down 4.7% on Insider Selling

September 2 at 11:39 AM | marketbeat.com

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $118.21 Million Position in United Therapeutics Corporation $UTHR

September 2 at 5:11 AM | marketbeat.com

United Therapeutics (NASDAQ:UTHR) CEO Martine Rothblatt Sells 9,500 Shares of Stock

September 2 at 5:07 AM | insidertrades.com

Insider Selling: United Therapeutics (NASDAQ:UTHR) CEO Sells $4,855,355.00 in Stock

September 1 at 5:06 PM | marketbeat.com

Two Sigma Securities LLC Purchases 2,216 Shares of United Therapeutics Corporation $UTHR

September 1 at 5:43 AM | marketbeat.com

Van ECK Associates Corp Has $15.73 Million Stock Holdings in United Therapeutics Corporation $UTHR

September 1 at 5:19 AM | marketbeat.com

Insider Selling: United Therapeutics (NASDAQ:UTHR) CEO Sells $4,916,345.00 in Stock

August 31 at 5:06 PM | marketbeat.com

Public Employees Retirement System of Ohio Invests $13.99 Million in United Therapeutics Corporation $UTHR

August 31 at 5:12 AM | marketbeat.com

Headlands Technologies LLC Invests $4.46 Million in United Therapeutics Corporation $UTHR

August 31 at 4:16 AM | marketbeat.com

Corient Private Wealth LP Purchases New Holdings in United Therapeutics Corporation $UTHR

August 31 at 3:44 AM | marketbeat.com

Canada Pension Plan Investment Board Acquires New Position in United Therapeutics Corporation $UTHR

August 31 at 3:43 AM | marketbeat.com

Beacon Pointe Advisors LLC Buys New Shares in United Therapeutics Corporation $UTHR

August 31 at 3:28 AM | marketbeat.com

United Therapeutics highlights new data supporting two FDA filings

August 30, 2026 | seekingalpha.com

United Therapeutics Corporation $UTHR Stock Holdings Decreased by Wellington Management Group LLP

August 30, 2026 | marketbeat.com

Livforsakringsbolaget Skandia Omsesidigt Invests $19.70 Million in United Therapeutics Corporation $UTHR

August 29, 2026 | marketbeat.com

Jefferies Financial Group Inc. Acquires New Holdings in United Therapeutics Corporation $UTHR

August 29, 2026 | marketbeat.com

FDA Accepts United Therapeutics' NDA Filing for Ralinepag in PAH

August 28, 2026 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

COGT, UTHR, GMAB, and ASND Company Descriptions

Ascendis Pharma A/S NASDAQ:ASND

$266.52 -0.80 (-0.30%)

As of 10:22 AM Eastern

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.

Cogent Biosciences NASDAQ:COGT

$34.28 -0.30 (-0.85%)

As of 10:22 AM Eastern

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.

Genmab A/S NASDAQ:GMAB

$34.22 -0.01 (-0.01%)

As of 10:22 AM Eastern

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.

United Therapeutics NASDAQ:UTHR

$480.39 -11.63 (-2.36%)

As of 10:22 AM Eastern

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest COGT, UTHR, GMAB, and ASND Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest COGT, UTHR, GMAB, and ASND Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

COGT, UTHR, GMAB, and ASND Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

COGT, UTHR, GMAB, and ASND Company Descriptions

Ascendis Pharma A/S NASDAQ:ASND

Cogent Biosciences NASDAQ:COGT

Genmab A/S NASDAQ:GMAB

United Therapeutics NASDAQ:UTHR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest COGT, UTHR, GMAB, and ASND Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest COGT, UTHR, GMAB, and ASND Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

COGT, UTHR, GMAB, and ASND Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

COGT, UTHR, GMAB, and ASND Company Descriptions

Ascendis Pharma A/S NASDAQ:ASND

Cogent Biosciences NASDAQ:COGT

Genmab A/S NASDAQ:GMAB

United Therapeutics NASDAQ:UTHR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools